Pharming Group N.V. PHAR · NASDAQ
$9.36 -2.80% (-$0.27)
Summary
49 / 100 · Bulios Score
What speaks for it
- Revenue grew by 22% a year over the last 3 years.
- It holds more cash than debt: $158.3M against $113.3M.
What to watch
- Earnings per share fell by 37% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 2.5 USD is left as net profit.
- Operating profit covers the interest on its debt only 2.1 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 73.5 USD for 1 USD of yearly profit. Over the last five years it was 184.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 22% a year. Earnings per share fell by 37% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 13 USD
- Research and development 31 USD
- Sales and administration 52 USD
- Taxes and other 0.8 USD
- Net profit 2.5 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 2.5 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 3.6 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $39 is 317% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 100%
UNITED STATES brings in 100% of revenue.
Segments in detail